|Nome||Titolo||Retribuzione||Esercitate||Anno di nascita|
|Mr. Mauro Severino Ajani||Founder & Exec. Chairman||435,5k||N/D||1955|
|Mr. Alessandro E. Della Cha LL.M||CEO & Exec. Director||659,95k||N/D||1963|
|Mr. Ngo Dinh Nhan||Head of R&D - AI & Biomedical IT||N/D||N/D||1979|
|Mr. Giulio Evangelisti||Head of Production, AI & Biomedical IT||N/D||N/D||1970|
|Mr. Niall Donnelly||Chief Financial Officer||N/D||N/D||1972|
|Mr. Marco Lecchi||Chief Operating Officer||N/D||N/D||1964|
|Mr. Davide Malavasi||Qualified Person & Technical Director||N/D||N/D||1973|
|Mr. Luigi Longo||Chief Scientific Officer||N/D||N/D||1979|
|Ms. Hazel Winchester||Head of Investor Relations||N/D||N/D||1971|
|Mr. Biagio Vigano||Chief People Officer||N/D||N/D||1974|
Cosmo Pharmaceuticals N.V., a specialty pharmaceutical company, focuses on the development and commercialization products for gastroenterology and endoscopy worldwide. It offers Lialda/Mezavant/Mesavancol and UCERIS/Cortiment, an oral tablet formulation for remission in active, mild to moderate ulcerative colitis; GI Genius, a system that uses artificial intelligence to detect colorectal polyps; and Methylene Blue MMX, diagnostic drug to enhance pre-cancerous and cancerous detection of colorectal lesions during colonoscopy. The company also provides Eleview, an injectable composition for use in gastrointestinal endoscopic procedures for submucosal lift of polyps, adenomas, early-stage cancers, or other gastrointestinal mucosal lesions; Aemcolo/Relafalk, a pharmaceutical product used for the treatment of traveler's diarrhea, uncomplicated acute diverticulitis, minimal hepatic encephalopathy, and small intestine bacterial overgrowth; and Winlevi, an androgen receptor inhibitor for acne vulgaris. In addition, it offers Clascoterone, an androgen receptor inhibitor that targets in the scalp and androgenetic alopecia; Rifamycin for irritable bowel syndrome with diarrhoea; ByFavo (Remimazolam), a fast-acting intravenous benzodiazepine agent for procedural sedation; CB-03-10, an oral androgen receptor antagonist for treatment against solid tumors; CB-01-33 for bile acid diarrhea; and Qolotag, a single use enema formulation. The company has a license agreement with RedHill Biopharma Ltd.; and Acacia Pharma Group plc. Cosmo Pharmaceuticals N.V. was founded in 1997 and is headquartered in Dublin, Ireland.
L'ISS Governance QualityScore di Cosmo Pharmaceuticals N.V. al N/D è N/D. I criteri di valutazione fondamentali sono revisione: N/D; Consiglio di Amministrazione: N/D; diritti degli azionisti: N/D; retribuzione: N/D.